Related Experiment Video

Updated: Jul 30, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol

F G Dunn, H O Ventura, F H Messerli

    Circulation
    |August 1, 1987
    PubMed

    Insights

    Atenolol effectively treats hypertension, leading to left ventricular hypertrophy regression as early as 4 weeks. This blood pressure control improves cardiac structure without impairing systolic function.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Left ventricular hypertrophy (LVH) regression is a known effect of antihypertensive drugs.
    • The precise timeline for LVH regression during treatment remains unclear.

    Purpose of the Study:

    • To define the time course of left ventricular hypertrophy regression in patients with essential hypertension treated with atenolol.
    • To assess the impact of atenolol on cardiac structure and function over one year.

    Main Methods:

    • 12 patients with essential hypertension received atenolol for one year.
    • Echocardiograms were performed at baseline and seven times serially.
    • Blood pressure, heart rate, and cardiac structural parameters were monitored.

    Main Results:

    • Atenolol significantly reduced blood pressure and heart rate.
    • Posterior and septal wall thicknesses decreased significantly by 4 weeks.
    • Left ventricular mass showed a statistically significant reduction by 6 months.

    Conclusions:

    • Regression of left ventricular hypertrophy begins as early as 4 weeks with atenolol therapy.
    • Atenolol-induced blood pressure control leads to sustained LVH regression without compromising left ventricular systolic function.

    More Related Videos

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy08:34

    Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

    Published on: September 25, 2017

    Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

    Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

    Published on: July 14, 2021

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Aortic Regurgitation II: Clinical Features and Diagnostic Tests01:22

    Aortic Regurgitation II: Clinical Features and Diagnostic Tests

    Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
    Aortic Regurgitation III: Medical Management01:25

    Aortic Regurgitation III: Medical Management

    Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
    Hypertension II: Pathophysiology01:29

    Hypertension II: Pathophysiology

    Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
    Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

    Hypertension III: Clinical Manifestations and Diagnostic Studies

    Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
    Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

    Hypertension IV: Drug Therapy and Lifestyle Modifications

    Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...